Paper Review Records
All Paper Review Records
26 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells
Stephanie C. Pitts; Carolina Celades; Nicole J. Toney; Megan T. Lynch; Natalie F. McMyn; Lisa K. Poppe; Shantel Angstadt; Claudia Palena; Thomas J. Meyer; Margaret Cam; Patrick Soon‐Shiong; Nicholas B. La Thangue; David Kerr; Sofia R. Gameiro; Jeffrey Schlom; Renee N. DonahueShow moreShow less
1. Center for Immuno‐Oncology, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland USA; 2. CCR Collaborative Bioinformatics Resource, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland USA; 3. ImmunityBio San Diego California USA; 4. IngenOx Therapeutics Oxford UKShow moreShow less
Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling
Yen‐Lin Lai; Jin‐Yuan Shih; Ching‐Chow ChenShow moreShow less
1. Department and Graduate Institute of Pharmacology, College of Medicine National Taiwan University Taipei Taiwan; 2. Department of Internal Medicine National Taiwan University Hospital Taipei TaiwanShow moreShow less
An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis
Kangchan Choi; Sang‐Hyeon Yoo; Ki‐Jong RheeShow moreShow less
1. Regeneration Medicine Research Center Yonsei University Wonju College of Medicine Republic of Korea; 2. School of Medicine Trinity Medical Sciences University Kingstown Saint Vincent and the Grenadines; 3. Department of Biomedical Laboratory Science, College of Health Sciences, MIRAE Campus Yonsei University Wonju Republic of KoreaShow moreShow less
Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas
Stefanos Arampatzis; Tereza Buchtová; Jirina Bartkova; Marie Lund Bay; Christoffer Lynge Halvorsen; Zuzana Machacova; Zdenek Skrott; Martin Mistrik; Ekaterina Dulina; Miguel Andujar‐Sanchez; Estrid Høgdall; Tine Henrichsen Schnack; Claus Høgdall; Berit Jul Mosgaard; Marie Boennelycke; Jacob Brink Laursen; Allan Jensen; Susanne K. Kjær; Tuula Kallunki; Robert Strauss; Jiri BartekShow moreShow less
1. Genome Integrity Group Danish Cancer Institute, Danish Cancer Society Copenhagen Denmark; 2. Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory Karolinska Institute Stockholm Sweden; 3. Cancer Invasion and Resistance Group Danish Cancer Institute, Danish Cancer Society Copenhagen Denmark; 4. Faculty of Medicine and Dentistry Institute of Molecular and Translational Medicine, Palacky University Olomouc Czech Republic; 5. Department of Pathology Complejo Hospitalario Universitario Insular Las Palmas Gran Canaria Spain; 6. Molecular Unit, Department of Pathology Copenhagen University Hospital, Herlev and Gentofte Hospital Denmark; 7. Department of Gynaecology Copenhagen University Hospital Rigshospitalet Denmark; 8. Department of Clinical Medicine University of Copenhagen Denmark; 9. Department of Pathology Copenhagen University Hospital Rigshospitalet Denmark; 10. Virus, Lifestyle and Genes Group Danish Cancer Institute, Danish Cancer Society Copenhagen Denmark; 11. Translational and Clinical Pharmacology, Department of Drug Design and Pharmacology University of Copenhagen Denmark; 12. Division of Cancer Research, Ninewells Hospital and Medical School University of Dundee UKShow moreShow less
The multifaceted roles of lysosomes in cancer
Jia Li; Kevin M. RyanShow moreShow less
1. Cancer Research UK Scotland Institute Glasgow UK; 2. School of Cancer Sciences University of Glasgow UKShow moreShow less
Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling
Elen Telumyan; Beatriz Martín‐Gracia; Eva Bassols‐Citores; Krizia Sagini; Maria K. Andersen; Tuula A. Nyman; May‐Britt Tessem; Morten B. Rye; Alicia LlorenteShow moreShow less
1. Department of Circulation and Medical Imaging NTNU Trondheim Norway; 2. Department of Molecular Cell Biology, Institute for Cancer Research Oslo University Hospital‐The Norwegian Radium Hospital Oslo Norway; 3. Centre for Cancer Cell Reprogramming, Faculty of Medicine University of Oslo Norway; 4. Department of Immunology University of Oslo and Oslo University Hospital Norway; 5. Clinic of Surgery, St. Olavs Hospital Trondheim University Hospital Norway; 6. Department of Clinical and Molecular Medicine NTNU Trondheim NorwayShow moreShow less
FAQ
How long does Molecular Oncology take to review a manuscript?
As of 2026-11-17, CrushSCI has 26 complete review records for Molecular Oncology. The fastest paper went from submission to acceptance in 2 days (Weakening the nuclear envelope: Lamin B receptor in melanoma metastasis, received 2026-05-04, accepted 2026-05-06); the slowest took 317 days. The average is 135.8 days and the median is 133.5 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
